Skip to content
Open access

Second-line chemotherapy efficacy is not affected by prior exposure to immunotherapy in extensive-disease small-cell lung cancer: results from the ESME French national real-world cohort

Aug 2026 · ESMO Open · Vol 11, pp. 108324 · 0 citations · 26 references
Medicine

TL;DR

This study showed no OS gain in second-line treatment among patients pretreated with immunotherapy compared with those who received chemotherapy alone as first-line treatment.

Abstract

Background Extensive-disease small-cell lung cancer (ED-SCLC) is an aggressive disease with limited effective therapeutic options. Clinical trials suggest an additive effect of chemotherapy and immunotherapy in SCLC, although the magnitude of benefit seems to be limited. Considering the prolonged peripheral persistence of anti-PD-(L)1 blockade, we wanted to investigate the impact of prior immunotherapy exposure on the efficacy of second-line chemotherapy. Patients and methods Using the Epidemio-Strategy and Medical Economics lung cancer national real-world database, we selected ED-SCLC patients diagnosed between 17 February 2010 and 4 December 2023 who had received at least two lines of treatment for a metastatic disease with platinum-based regimens in the first-line setting. Second-line real-world progression-free survival (rw-PFS) and overall survival (OS) were analyzed according to first-line immunotherapy exposure using a multivariable Cox proportional hazards model and a propensity score-weighted sensitivity analysis. Results The study included 2051 patients with ED-SCLC: 638 (30%) in the immunotherapy-pretreated group and 1413 (70%) who received only first-line chemotherapy. Multivariable analysis showed no significant difference in second-line median rw-PFS between immunotherapy-pretreated patients [2.9 months, 95% confidence interval (CI) 2.7-3.3] and chemotherapy-only pretreated patients (2.5 months, 95% CI 2.4-2.7) (hazard ratio 0.94, 95% CI 0.85-1.04, P = 0.21). Similar results were observed in the propensity score adjusted Cox regression sensitivity analysis. A longer median OS from the start of second-line treatment was observed in immunotherapy-pretreated patients (6.6 months, 95% CI 6.1-7.1 compared with 5.7 months, 95% CI 5.4-6.1, P = 0.03) although, this result has not been confirmed in a more contemporary cohort. Conclusion This study showed no OS gain in second-line treatment among patients pretreated with immunotherapy compared with those who received chemotherapy alone as first-line treatment.

Read PDF

Similar papers

Review Open access Sep 2026

Second-line therapy in extensive-stage small cell lung cancer: an unmet need highlighted by real-world evidence from the LALUCA registry.

This real-world analysis shows poor outcomes in patients with progressing ES-SCLC, reflected by both short median PFS and duration of second-line treatment, along with high rates of treatment discontinuation due to progression, highlighting the urgent need for more effective and tolerable treatment options.

Daniel Moser, A. Lang-Stöberl, H. Fabikan et al. · 0 citations
Review Open access Sep 2026

Efficacy and safety of first-line immunotherapy-related induction and maintenance therapy for extensive-stage small cell lung cancer: a systematic review and Bayesian network meta-analysis

Background Extensive-stage small cell lung cancer (ES-SCLC) is highly aggressive with dismal prognosis, and platinum monochemotherapy offers modest long-term survival. Multiple first-line regimens integrating immunotherapy, anti-angiogenic agents and chemotherapy have been approved, yet direct head-to-head comparisons...

Hong-Jing Yu, Jun-Chen Liu, Dong-Sheng Zhang et al. · 0 citations
Open access Sep 2026

Treatment-free interval as a determinant of second-line chemotherapy outcomes in extensive-stage small cell lung cancer: a Dutch population-based study.

For patients with a CFI exceeding 90 days, platinum rechallenge represents a rational second-line treatment strategy and remains relevant despite the introduction of first-line chemoimmunotherapy, as a substantial proportion of patients still relapse within 180 days.

A. Eijkelboom, B. Peters, D. Dumoulin et al. · 0 citations
Open access 2026

Efficacy and Safety of First-Line Chemoimmunotherapy with Durvalumab or Atezolizumab in Extensive-Stage of Small-Cell Lung Cancer in Real World Practice

The type of immune checkpoint inhibitor used in combination with chemotherapy did not significantly influence treatment outcomes, however, the presence of liver metastases emerged as a major adverse prognostic factor associated with shorter OS and PFS in patients with ES-SCLC treated with chemoimmunotherapy.

A. Łomża-Łaba, M. Knetki-Wróblewska, Michał Gil et al. · 0 citations
Open access Sep 2026

Greater survival benefits in small cell lung cancer patients: a real-world study with immune checkpoint inhibitors therapy

Real-world evidence is provided supporting the use of ICI-based therapy in SCLC, particularly in advanced-stage disease, but should be interpreted cautiously given the retrospective design and subgroup sample sizes.

Peng-Hu Gao, Hong-Bing Zhang, Ming-Hui Liu et al. · 0 citations
Open access Sep 2026

First-line immunotherapy for patients with metastatic non-small cell lung cancer not eligible for a platinum-based chemotherapy

Immune checkpoint inhibitors alone or in combination with platinum-based doublet chemotherapy is the standard first-line treatment for patients with metastatic non-small cell lung cancer (mNSCLC) without driver mutations. It should be recognized, however, that treating patients who are not eligible for platinum-based c...

A. Kornietskaya, S. Evdokimova, N. S. Prizova et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.